Business Wire

Sephora Reveals Lady Gaga “We Belong to Something Beautiful” Campaign and special collaboration during World Pride Month

Share

Today, Sephora proudly unveils its “We Belong To Something Beautiful” signature campaign with Haus Labs By Lady Gaga in partnership with Born This Way Foundation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528841282/en/

A Shared Vision: Lady Gaga and Sephora Champion Beauty and Belonging

At the heart of this campaign is a new film featuring Lady Gaga sharing her vision of beauty as being part of a kind, inclusive, joyful, inspiring community, where everyone can safely explore and express themselves, mirroring Sephora’s purpose and vision. The film highlights “Classes for Confidence,” a program that brings community members together around a shared passion for beauty and storytelling.

“At Sephora, we're driven by our Purpose to champion a world of inspiration and inclusion where everyone can celebrate their beauty,” said Deborah Yeh, Global Chief Marketing Officer of Sephora. “Lady Gaga’s personal story is a magnificent illustration of the values we promote every day and having her sharing her own feeling about what Sephora is all about is an incredible testimony for us.”

Sephora celebrates Pride by Supporting Youth Mental Health Through the Kindness in Community Fund

From June 1 through June 30, $1 USD from every Haus Labs product purchased at Sephora (or the equivalent in local currency) will be donated to Born This Way Foundation*, a nonprofit organization co-founded by Lady Gaga and her mother, Cynthia Germanotta, that empowers and inspires young people to build a kinder and braver world that supports their mental health.

Haus Labs is built on the belief that artistry and self-expression are tools of empowerment,” said Angela Simpson, Chief Marketing Officer, Haus Labs by Lady Gaga. “This campaign is about showing up as you are and celebrating what makes each of us unique. We’re proud to partner with Sephora to support the next generation of changemakers."

Donations will go to Born This Way Foundation’s Kindness in Community Fund, a youth-driven global grantmaking program funding grassroots organizations that support the mental health and wellbeing of young people by providing safe community spaces and resources that meet their needs, reflecting both Sephora’s and Born This Way Foundation’s deep commitment to building a kinder, braver world for young people.

Born This Way Foundation has always been driven by the passion and leadership of young people, a vision my daughter, Lady Gaga, and I shared from the start," said Cynthia Germanotta, President and Co-founder of Born This Way Foundation. "We’re honored to partner with Sephora and Haus Labs to reach even more young people with the message that they are seen, valued, and supported.”

Sephora and Born This Way Foundation invite the public to nominate organizations making a positive impact for LGBTQIA+ communities, to receive these grants. Nominations will be accepted through Born This Way Foundation’s website until June 30, and final grantees will be announced by December 2025.

We are proud to leverage the power of our brand and our community to raise awareness around inclusivity and to support the mission of the Kindness in Community Fund. We hope to make a big impact thanks to the mobilization of our community of 74 million members,”said Deborah Yeh.

With Sephora’s global reach, donations will be directed from 20 markets where SEPHORA operates, including Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, Hong Kong SAR, Italy, Poland, Portugal, Romania, Serbia, Singapore, Spain, Sweden, Switzerland, Thailand, the United Kingdom and the United States*.

*Up to a max of $500,000 only in the US.

Brave Spaces

Through Pride Month, and for the second year in a row, Sephora will bring back its “Brave Spaces” * in selected stores around the world, to offer a welcoming environment for LGBTQIA+ community members and allies at Pride to safely create their Pride looks and, if they wish so, have them removed after Pride celebrations. Trained Sephora Beauty Advisors are at the very heart of this program and will guide and offer visitors to freely create their Pride looks. Rooted in supporting and inspiring people not only during Pride but all year round, Brave Spaces will provide a place for the LGBTQIA+ community to feel comfortable expressing their true self in a welcoming environment.

*Brave Spaces are popping up in key Sephora stores worldwide, including 74 cities across 21 markets — Canada, the US, Brazil, Mexico, France, the Czech Republic, Poland, the UK, Germany, Sweden, Denmark, Switzerland, Greece, Italy, Spain, Portugal, Australia, New Zealand, Hong Kong, Thailand, and Singapore.

About Sephora

Sephora is the world’s leading global prestige beauty retail brand. With 56,000 passionate employees operating in 35 markets, Sephora connects customers and beauty brands within the world’s most trusted and dynamic beauty community. We serve a highly engaged community of hundreds of millions of beauty followers across our global omnichannel network of more than 3,200 stores and iconic flagships, and our e-commerce and digital platforms, offering personalized and immersive seamless experiences across every touchpoint. With our curation of close to 500 brands and our own label, Sephora Collection, we offer the most unique and diverse range of prestige beauty products, tailored to our customers’ needs from fragrance to make-up, haircare, skincare and beyond, as we constantly reimagine the world of prestige beauty.

Since our inception in 1969 in Limoges, France, and as part of the LVMH Group since 1997, we have been disrupting the prestige beauty retail industry. Today, we continue to break with convention to drive our mission to expand the way the world sees beauty and empower the extraordinary in each of us.

About Born This Way Foundation

Born This Way Foundation, co-founded and led by Lady Gaga and her mother, Cynthia Bissett Germanotta, empowers and inspires young people to build a kinder, braver world that supports their mental health and wellbeing. Based on the scientific link between kindness and mental health and built in partnership with young people, the Foundation leverages research, programs, grantmaking, and partnerships to engage young people and connect them with accessible mental health resources. This approach comes to life through the storytelling platform Channel Kindness, the mental health training course Be There Certificate, the youth-led grantmaking program Kindness in Community Fund, and more, reaching thousands of young people around the world each year. Learn more at bornthisway.foundation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250528841282/en/

Contacts

Sephora
Marion Bouchut
mbouchut@sephora.fr
+33 6 34 45 34 09

Haus Labs By Lady Gaga
Crissy Tang
hauslabspr@cmmpr.com
717-617-9370

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye